| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Organ Transplantation | 57 | 2024 | 1130 | 10.380 |
Why?
|
| Cytomegalovirus Infections | 33 | 2024 | 823 | 9.680 |
Why?
|
| Kidney Transplantation | 38 | 2024 | 4091 | 5.120 |
Why?
|
| Cytomegalovirus | 21 | 2024 | 747 | 4.420 |
Why?
|
| Immunocompromised Host | 25 | 2024 | 846 | 3.190 |
Why?
|
| Antiviral Agents | 29 | 2024 | 3013 | 2.890 |
Why?
|
| Tissue Donors | 26 | 2023 | 2206 | 2.270 |
Why?
|
| Medical Tourism | 5 | 2021 | 51 | 2.070 |
Why?
|
| Communicable Diseases | 13 | 2023 | 869 | 2.000 |
Why?
|
| Respiratory Syncytial Virus Vaccines | 4 | 2024 | 33 | 1.570 |
Why?
|
| Parasitic Diseases | 4 | 2013 | 76 | 1.570 |
Why?
|
| Liver Transplantation | 10 | 2022 | 2204 | 1.500 |
Why?
|
| Opportunistic Infections | 6 | 2018 | 376 | 1.260 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 14 | 2023 | 5465 | 1.250 |
Why?
|
| Vaccines | 6 | 2022 | 817 | 1.250 |
Why?
|
| Respiratory Syncytial Virus Infections | 4 | 2024 | 346 | 1.140 |
Why?
|
| Travel Medicine | 5 | 2019 | 81 | 1.140 |
Why?
|
| Virus Diseases | 5 | 2015 | 722 | 1.080 |
Why?
|
| Acetates | 4 | 2023 | 318 | 1.080 |
Why?
|
| Dermatomycoses | 3 | 2011 | 47 | 1.020 |
Why?
|
| Kidney Failure, Chronic | 4 | 2022 | 2448 | 1.020 |
Why?
|
| Tissue and Organ Procurement | 8 | 2021 | 889 | 0.990 |
Why?
|
| Lung Transplantation | 5 | 2022 | 1271 | 0.940 |
Why?
|
| Donor Selection | 5 | 2021 | 203 | 0.880 |
Why?
|
| Herpesviridae Infections | 2 | 2022 | 270 | 0.850 |
Why?
|
| Immunity, Cellular | 4 | 2022 | 1548 | 0.830 |
Why?
|
| Travel | 5 | 2024 | 783 | 0.830 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2024 | 235 | 0.820 |
Why?
|
| Respiratory Syncytial Virus, Human | 4 | 2024 | 142 | 0.760 |
Why?
|
| Vaccination | 12 | 2023 | 3282 | 0.750 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 4 | 2012 | 443 | 0.730 |
Why?
|
| Herpesvirus 3, Human | 1 | 2021 | 157 | 0.720 |
Why?
|
| Anti-Infective Agents | 5 | 2022 | 972 | 0.690 |
Why?
|
| Bacteremia | 2 | 2024 | 967 | 0.670 |
Why?
|
| Ganciclovir | 6 | 2024 | 253 | 0.660 |
Why?
|
| Herpes Simplex | 1 | 2022 | 470 | 0.660 |
Why?
|
| Dengue | 1 | 2022 | 256 | 0.650 |
Why?
|
| DNA Virus Infections | 1 | 2018 | 15 | 0.650 |
Why?
|
| Torque teno virus | 1 | 2018 | 13 | 0.640 |
Why?
|
| Living Donors | 2 | 2021 | 612 | 0.620 |
Why?
|
| Humans | 156 | 2024 | 746070 | 0.600 |
Why?
|
| Influenza Vaccines | 5 | 2012 | 745 | 0.590 |
Why?
|
| Latent Tuberculosis | 3 | 2021 | 220 | 0.590 |
Why?
|
| Graft Rejection | 7 | 2022 | 4203 | 0.590 |
Why?
|
| Tuberculosis | 3 | 2023 | 1956 | 0.570 |
Why?
|
| Propensity Score | 1 | 2024 | 1848 | 0.570 |
Why?
|
| Disease Transmission, Infectious | 6 | 2017 | 556 | 0.570 |
Why?
|
| Cytomegalovirus Vaccines | 2 | 2020 | 17 | 0.530 |
Why?
|
| Monitoring, Immunologic | 2 | 2013 | 95 | 0.510 |
Why?
|
| Dichlororibofuranosylbenzimidazole | 2 | 2024 | 16 | 0.480 |
Why?
|
| Encephalitozoonosis | 1 | 2014 | 2 | 0.480 |
Why?
|
| Encephalitozoon cuniculi | 1 | 2014 | 5 | 0.480 |
Why?
|
| Hepatitis E | 1 | 2015 | 75 | 0.480 |
Why?
|
| Quinazolines | 2 | 2021 | 1350 | 0.470 |
Why?
|
| Enzyme-Linked Immunospot Assay | 3 | 2022 | 126 | 0.470 |
Why?
|
| Ribonucleosides | 2 | 2024 | 78 | 0.460 |
Why?
|
| Budd-Chiari Syndrome | 1 | 2013 | 24 | 0.450 |
Why?
|
| Ribavirin | 1 | 2015 | 394 | 0.450 |
Why?
|
| Anti-Bacterial Agents | 8 | 2024 | 7223 | 0.440 |
Why?
|
| Immunosuppressive Agents | 13 | 2022 | 4055 | 0.440 |
Why?
|
| Advisory Committees | 7 | 2023 | 768 | 0.440 |
Why?
|
| Pandemics | 8 | 2024 | 8434 | 0.430 |
Why?
|
| Jaundice | 1 | 2013 | 89 | 0.430 |
Why?
|
| Epidemics | 1 | 2018 | 507 | 0.410 |
Why?
|
| Aspergillosis | 2 | 2019 | 244 | 0.400 |
Why?
|
| Vancomycin Resistance | 1 | 2012 | 126 | 0.400 |
Why?
|
| Enterococcus faecium | 1 | 2012 | 100 | 0.390 |
Why?
|
| Mycobacterium kansasii | 1 | 2011 | 8 | 0.390 |
Why?
|
| Transplants | 4 | 2022 | 205 | 0.390 |
Why?
|
| Drug Resistance, Viral | 7 | 2024 | 837 | 0.390 |
Why?
|
| Clonorchis sinensis | 1 | 2010 | 3 | 0.380 |
Why?
|
| Alternaria | 1 | 2011 | 42 | 0.370 |
Why?
|
| Liver Abscess | 1 | 2011 | 80 | 0.370 |
Why?
|
| Influenza, Human | 5 | 2017 | 1502 | 0.370 |
Why?
|
| Practice Guidelines as Topic | 13 | 2021 | 7272 | 0.370 |
Why?
|
| Trichophyton | 1 | 2010 | 19 | 0.360 |
Why?
|
| Adenovirus Infections, Human | 1 | 2011 | 73 | 0.360 |
Why?
|
| Malacoplakia | 2 | 2021 | 14 | 0.360 |
Why?
|
| Meningitis, Bacterial | 1 | 2012 | 220 | 0.360 |
Why?
|
| Pancreas Transplantation | 1 | 2011 | 190 | 0.350 |
Why?
|
| Salmonella Vaccines | 2 | 2006 | 9 | 0.350 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2012 | 337 | 0.350 |
Why?
|
| Transplantation | 3 | 2017 | 217 | 0.340 |
Why?
|
| Postoperative Complications | 7 | 2022 | 15341 | 0.340 |
Why?
|
| Markov Chains | 1 | 2013 | 958 | 0.330 |
Why?
|
| Antiparasitic Agents | 3 | 2018 | 41 | 0.330 |
Why?
|
| Aspergillus | 2 | 2015 | 91 | 0.330 |
Why?
|
| End Stage Liver Disease | 1 | 2013 | 326 | 0.330 |
Why?
|
| Hepatitis B, Chronic | 1 | 2013 | 401 | 0.320 |
Why?
|
| Immunization | 5 | 2023 | 1219 | 0.320 |
Why?
|
| Hemochromatosis | 1 | 2010 | 170 | 0.320 |
Why?
|
| Nephrotic Syndrome | 1 | 2013 | 389 | 0.320 |
Why?
|
| Cytosine | 2 | 2022 | 211 | 0.320 |
Why?
|
| Schistosomiasis mansoni | 1 | 2009 | 90 | 0.320 |
Why?
|
| Cecum | 1 | 2009 | 230 | 0.320 |
Why?
|
| Steroids | 2 | 2013 | 919 | 0.310 |
Why?
|
| Schistosoma mansoni | 1 | 2009 | 153 | 0.310 |
Why?
|
| Preventive Health Services | 1 | 2013 | 568 | 0.300 |
Why?
|
| Respiratory Tract Diseases | 2 | 2023 | 740 | 0.300 |
Why?
|
| Bacterial Infections | 2 | 2014 | 1395 | 0.300 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2010 | 366 | 0.300 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 2008 | 111 | 0.290 |
Why?
|
| Adenoviridae | 1 | 2011 | 1079 | 0.280 |
Why?
|
| Zoonoses | 2 | 2007 | 178 | 0.280 |
Why?
|
| Antifungal Agents | 3 | 2019 | 706 | 0.270 |
Why?
|
| Coccidioides | 1 | 2006 | 18 | 0.270 |
Why?
|
| Coccidioidomycosis | 1 | 2006 | 37 | 0.260 |
Why?
|
| Heart Transplantation | 5 | 2021 | 3032 | 0.260 |
Why?
|
| Renal Dialysis | 3 | 2024 | 1692 | 0.260 |
Why?
|
| Gene Products, gag | 1 | 2006 | 323 | 0.260 |
Why?
|
| Hand | 1 | 2011 | 876 | 0.260 |
Why?
|
| Risk Factors | 24 | 2024 | 72413 | 0.250 |
Why?
|
| Bacteriological Techniques | 1 | 2006 | 277 | 0.250 |
Why?
|
| Salmonella Infections | 1 | 2006 | 167 | 0.240 |
Why?
|
| Salmonella typhi | 1 | 2006 | 198 | 0.240 |
Why?
|
| Trypanosoma cruzi | 2 | 2018 | 199 | 0.240 |
Why?
|
| Registries | 2 | 2018 | 8170 | 0.240 |
Why?
|
| Adult | 39 | 2024 | 214969 | 0.230 |
Why?
|
| Salmonella typhimurium | 1 | 2006 | 339 | 0.230 |
Why?
|
| Benzimidazoles | 3 | 2024 | 857 | 0.230 |
Why?
|
| Hepatitis B virus | 3 | 2017 | 513 | 0.230 |
Why?
|
| Endemic Diseases | 2 | 2018 | 185 | 0.220 |
Why?
|
| Foscarnet | 1 | 2022 | 35 | 0.220 |
Why?
|
| Chemoprevention | 2 | 2023 | 325 | 0.210 |
Why?
|
| Immunization Schedule | 3 | 2023 | 220 | 0.210 |
Why?
|
| HIV Seropositivity | 1 | 2008 | 959 | 0.210 |
Why?
|
| Male | 41 | 2024 | 351098 | 0.210 |
Why?
|
| Acyclovir | 1 | 2022 | 266 | 0.200 |
Why?
|
| Administration, Oral | 2 | 2024 | 3966 | 0.200 |
Why?
|
| Hepatitis B | 3 | 2017 | 692 | 0.200 |
Why?
|
| Consensus | 5 | 2024 | 3011 | 0.190 |
Why?
|
| Herpes Zoster Vaccine | 1 | 2022 | 47 | 0.190 |
Why?
|
| Liver | 4 | 2013 | 7371 | 0.190 |
Why?
|
| Hepatitis C, Chronic | 2 | 2020 | 1027 | 0.190 |
Why?
|
| Protozoan Vaccines | 2 | 2012 | 13 | 0.190 |
Why?
|
| Rectum | 1 | 2006 | 898 | 0.190 |
Why?
|
| Anthozoa | 1 | 2021 | 65 | 0.190 |
Why?
|
| Infection Control | 1 | 2008 | 972 | 0.190 |
Why?
|
| Serotonin Syndrome | 1 | 2020 | 18 | 0.190 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2022 | 243 | 0.190 |
Why?
|
| Middle Aged | 33 | 2024 | 214419 | 0.190 |
Why?
|
| Treatment Outcome | 13 | 2024 | 63664 | 0.190 |
Why?
|
| Hemofiltration | 1 | 2021 | 55 | 0.180 |
Why?
|
| Nephrology | 1 | 2024 | 236 | 0.180 |
Why?
|
| Histoplasmosis | 1 | 2020 | 63 | 0.180 |
Why?
|
| Neoplasms | 8 | 2021 | 21681 | 0.180 |
Why?
|
| Feces | 1 | 2006 | 1430 | 0.170 |
Why?
|
| Azithromycin | 1 | 2021 | 196 | 0.170 |
Why?
|
| AIDS Vaccines | 1 | 2006 | 895 | 0.170 |
Why?
|
| Liver Cirrhosis | 1 | 2010 | 1875 | 0.170 |
Why?
|
| Viremia | 2 | 2023 | 724 | 0.170 |
Why?
|
| Intestines | 2 | 2009 | 1892 | 0.170 |
Why?
|
| Antibiotic Prophylaxis | 3 | 2022 | 628 | 0.170 |
Why?
|
| Herpes Zoster | 1 | 2022 | 240 | 0.170 |
Why?
|
| Vaccines, Attenuated | 3 | 2011 | 314 | 0.170 |
Why?
|
| Microbiological Techniques | 1 | 2020 | 99 | 0.170 |
Why?
|
| T-Lymphocytes | 2 | 2019 | 10018 | 0.170 |
Why?
|
| Mycoses | 1 | 2022 | 383 | 0.170 |
Why?
|
| Isoniazid | 1 | 2020 | 281 | 0.160 |
Why?
|
| Biopsy | 5 | 2013 | 6732 | 0.160 |
Why?
|
| Pneumonia | 2 | 2024 | 2110 | 0.160 |
Why?
|
| Death | 2 | 2018 | 665 | 0.160 |
Why?
|
| Antigens | 1 | 2004 | 1438 | 0.160 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2019 | 3782 | 0.160 |
Why?
|
| Mass Screening | 2 | 2021 | 5329 | 0.160 |
Why?
|
| Bacterial Vaccines | 2 | 2012 | 397 | 0.160 |
Why?
|
| Drug Approval | 2 | 2022 | 808 | 0.150 |
Why?
|
| Viral Matrix Proteins | 1 | 2019 | 197 | 0.150 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2013 | 3896 | 0.150 |
Why?
|
| Simplexvirus | 1 | 2021 | 798 | 0.150 |
Why?
|
| Viral Vaccines | 2 | 2013 | 594 | 0.150 |
Why?
|
| Urinary Tract Infections | 1 | 2024 | 801 | 0.150 |
Why?
|
| Attitude of Health Personnel | 1 | 2011 | 3820 | 0.150 |
Why?
|
| Rhodococcus | 1 | 2017 | 13 | 0.150 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2024 | 1694 | 0.150 |
Why?
|
| Incidence | 5 | 2024 | 20812 | 0.140 |
Why?
|
| Escherichia coli Infections | 1 | 2021 | 522 | 0.140 |
Why?
|
| Female | 30 | 2024 | 382129 | 0.140 |
Why?
|
| Actinomycetales Infections | 1 | 2017 | 30 | 0.140 |
Why?
|
| Sequence Analysis, DNA | 2 | 2023 | 4704 | 0.140 |
Why?
|
| Candidemia | 1 | 2017 | 27 | 0.140 |
Why?
|
| United States | 18 | 2024 | 70368 | 0.140 |
Why?
|
| Polymyxins | 1 | 2016 | 19 | 0.140 |
Why?
|
| Diarrhea | 1 | 2023 | 1327 | 0.140 |
Why?
|
| Trimethoprim | 1 | 2016 | 85 | 0.140 |
Why?
|
| Prospective Studies | 7 | 2024 | 53219 | 0.130 |
Why?
|
| Immediate-Early Proteins | 1 | 2019 | 449 | 0.130 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2022 | 1624 | 0.130 |
Why?
|
| Chagas Disease | 1 | 2018 | 165 | 0.130 |
Why?
|
| Respiratory Tract Infections | 1 | 2023 | 985 | 0.130 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2010 | 2389 | 0.130 |
Why?
|
| Triazoles | 2 | 2019 | 903 | 0.130 |
Why?
|
| Bacteria | 2 | 2017 | 2136 | 0.130 |
Why?
|
| Neuroaspergillosis | 1 | 2015 | 2 | 0.130 |
Why?
|
| Immunomodulation | 2 | 2021 | 540 | 0.130 |
Why?
|
| Risk Assessment | 8 | 2018 | 23454 | 0.130 |
Why?
|
| Central Nervous System Fungal Infections | 1 | 2015 | 25 | 0.130 |
Why?
|
| Chagas Cardiomyopathy | 1 | 2015 | 70 | 0.120 |
Why?
|
| Retrospective Studies | 11 | 2024 | 78293 | 0.120 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2024 | 2055 | 0.120 |
Why?
|
| West Nile Fever | 1 | 2015 | 75 | 0.120 |
Why?
|
| West Nile virus | 1 | 2015 | 78 | 0.120 |
Why?
|
| Drug Prescriptions | 1 | 2024 | 1639 | 0.120 |
Why?
|
| Health Resources | 1 | 2020 | 906 | 0.120 |
Why?
|
| Tacrolimus | 2 | 2022 | 717 | 0.120 |
Why?
|
| Monitoring, Physiologic | 1 | 2022 | 1750 | 0.120 |
Why?
|
| Aged | 18 | 2024 | 164222 | 0.110 |
Why?
|
| Patient Education as Topic | 1 | 2024 | 2278 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 3 | 2024 | 5458 | 0.110 |
Why?
|
| Nitriles | 1 | 2019 | 946 | 0.110 |
Why?
|
| Antitubercular Agents | 2 | 2012 | 1347 | 0.110 |
Why?
|
| Autoimmune Diseases of the Nervous System | 1 | 2014 | 69 | 0.110 |
Why?
|
| Sudan | 1 | 2013 | 82 | 0.110 |
Why?
|
| Immune System | 1 | 2019 | 800 | 0.110 |
Why?
|
| Societies, Medical | 5 | 2019 | 3790 | 0.110 |
Why?
|
| Virginiamycin | 1 | 2012 | 11 | 0.110 |
Why?
|
| Disease Outbreaks | 1 | 2022 | 1732 | 0.110 |
Why?
|
| Bacterial Proteins | 1 | 2006 | 3785 | 0.110 |
Why?
|
| International Agencies | 1 | 2013 | 244 | 0.110 |
Why?
|
| Herpesvirus 6, Human | 1 | 2013 | 95 | 0.100 |
Why?
|
| Hepatitis C | 2 | 2020 | 1588 | 0.100 |
Why?
|
| Hepatorenal Syndrome | 1 | 2013 | 67 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2019 | 6453 | 0.100 |
Why?
|
| Daptomycin | 1 | 2012 | 71 | 0.100 |
Why?
|
| BK Virus | 1 | 2013 | 123 | 0.100 |
Why?
|
| Oxazolidinones | 1 | 2012 | 94 | 0.100 |
Why?
|
| Graft Survival | 3 | 2013 | 3599 | 0.100 |
Why?
|
| Cryptosporidiosis | 1 | 2012 | 53 | 0.100 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2021 | 1872 | 0.100 |
Why?
|
| Mycological Typing Techniques | 1 | 2011 | 7 | 0.100 |
Why?
|
| Facial Transplantation | 1 | 2014 | 220 | 0.100 |
Why?
|
| DNA, Ribosomal Spacer | 1 | 2011 | 24 | 0.100 |
Why?
|
| Clonorchiasis | 1 | 2010 | 5 | 0.100 |
Why?
|
| ROC Curve | 1 | 2019 | 3496 | 0.100 |
Why?
|
| Maxilla | 1 | 2014 | 480 | 0.090 |
Why?
|
| Antibody Formation | 3 | 2023 | 1379 | 0.090 |
Why?
|
| Length of Stay | 1 | 2024 | 6292 | 0.090 |
Why?
|
| Viral Core Proteins | 1 | 2011 | 161 | 0.090 |
Why?
|
| Communicable Disease Control | 1 | 2017 | 841 | 0.090 |
Why?
|
| Enteritis | 1 | 2012 | 161 | 0.090 |
Why?
|
| Acetamides | 1 | 2012 | 257 | 0.090 |
Why?
|
| Prosthesis-Related Infections | 1 | 2016 | 485 | 0.090 |
Why?
|
| Leukemia Virus, Murine | 1 | 2010 | 92 | 0.090 |
Why?
|
| Retroviridae Infections | 1 | 2010 | 143 | 0.090 |
Why?
|
| Subcutaneous Tissue | 1 | 2011 | 129 | 0.090 |
Why?
|
| Clinical Trials as Topic | 2 | 2023 | 7935 | 0.090 |
Why?
|
| Caregivers | 1 | 2022 | 2139 | 0.090 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2014 | 653 | 0.090 |
Why?
|
| DNA, Fungal | 1 | 2011 | 274 | 0.090 |
Why?
|
| Fatal Outcome | 3 | 2009 | 1825 | 0.080 |
Why?
|
| Health Services Needs and Demand | 1 | 2017 | 1389 | 0.080 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2010 | 170 | 0.080 |
Why?
|
| Adaptive Immunity | 1 | 2014 | 722 | 0.080 |
Why?
|
| Vaccines, Synthetic | 2 | 2022 | 600 | 0.080 |
Why?
|
| Interferon-gamma | 2 | 2023 | 3134 | 0.080 |
Why?
|
| Listeria monocytogenes | 1 | 2011 | 252 | 0.080 |
Why?
|
| Fungal Vaccines | 1 | 2008 | 7 | 0.080 |
Why?
|
| Inpatients | 1 | 2020 | 2512 | 0.080 |
Why?
|
| Histocytochemistry | 1 | 2010 | 690 | 0.080 |
Why?
|
| Fatigue Syndrome, Chronic | 1 | 2010 | 215 | 0.080 |
Why?
|
| Acute Kidney Injury | 1 | 2021 | 1841 | 0.080 |
Why?
|
| HIV-1 | 1 | 2006 | 6870 | 0.080 |
Why?
|
| Genetic Vectors | 2 | 2011 | 3346 | 0.080 |
Why?
|
| Debridement | 1 | 2011 | 494 | 0.080 |
Why?
|
| Comorbidity | 2 | 2021 | 10348 | 0.080 |
Why?
|
| Immunity, Mucosal | 1 | 2011 | 469 | 0.080 |
Why?
|
| Tumor Virus Infections | 1 | 2010 | 437 | 0.070 |
Why?
|
| Young Adult | 7 | 2021 | 57114 | 0.070 |
Why?
|
| Tachycardia, Sinus | 1 | 1997 | 42 | 0.070 |
Why?
|
| Cross Infection | 1 | 2017 | 1420 | 0.070 |
Why?
|
| Hepacivirus | 3 | 2020 | 1364 | 0.070 |
Why?
|
| Transplantation Immunology | 2 | 2010 | 509 | 0.070 |
Why?
|
| Nucleic Acids | 1 | 2010 | 177 | 0.070 |
Why?
|
| Nucleic Acid Amplification Techniques | 2 | 2021 | 330 | 0.070 |
Why?
|
| Amlodipine | 1 | 1997 | 80 | 0.070 |
Why?
|
| Renal Insufficiency | 1 | 2013 | 786 | 0.070 |
Why?
|
| Disease Vectors | 1 | 2007 | 61 | 0.070 |
Why?
|
| Antibodies, Viral | 3 | 2023 | 3075 | 0.070 |
Why?
|
| Pyridines | 1 | 2019 | 2841 | 0.070 |
Why?
|
| Peptides | 1 | 2019 | 4312 | 0.070 |
Why?
|
| Ambulatory Care | 1 | 2017 | 2717 | 0.070 |
Why?
|
| HIV Core Protein p24 | 1 | 2006 | 254 | 0.070 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2013 | 797 | 0.070 |
Why?
|
| Heart | 1 | 2019 | 4361 | 0.070 |
Why?
|
| U937 Cells | 1 | 2006 | 263 | 0.070 |
Why?
|
| Serologic Tests | 2 | 2018 | 369 | 0.070 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2006 | 363 | 0.070 |
Why?
|
| Fibrosis | 1 | 2013 | 2005 | 0.070 |
Why?
|
| Diagnosis, Differential | 4 | 2009 | 12839 | 0.070 |
Why?
|
| Brain Death | 1 | 2009 | 340 | 0.070 |
Why?
|
| Lymphocytic Choriomeningitis | 1 | 2006 | 133 | 0.060 |
Why?
|
| Brain Diseases | 1 | 2015 | 1541 | 0.060 |
Why?
|
| Animals | 10 | 2021 | 166308 | 0.060 |
Why?
|
| Heart-Assist Devices | 1 | 2016 | 1243 | 0.060 |
Why?
|
| Lymphoma, T-Cell | 1 | 2008 | 302 | 0.060 |
Why?
|
| Lymphocytic choriomeningitis virus | 1 | 2006 | 173 | 0.060 |
Why?
|
| Immunologic Factors | 1 | 2014 | 1568 | 0.060 |
Why?
|
| Coma | 1 | 2009 | 483 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2022 | 9103 | 0.060 |
Why?
|
| North America | 2 | 2022 | 1264 | 0.060 |
Why?
|
| Child | 8 | 2017 | 78469 | 0.060 |
Why?
|
| Preoperative Care | 1 | 2013 | 2218 | 0.060 |
Why?
|
| Pulmonary Edema | 1 | 1997 | 406 | 0.060 |
Why?
|
| Calcium Channel Blockers | 1 | 1997 | 688 | 0.060 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2010 | 1338 | 0.060 |
Why?
|
| Drug Monitoring | 2 | 2021 | 948 | 0.060 |
Why?
|
| Babesia microti | 1 | 2003 | 31 | 0.060 |
Why?
|
| International Cooperation | 1 | 2010 | 1416 | 0.060 |
Why?
|
| United States Food and Drug Administration | 2 | 2022 | 1651 | 0.060 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2013 | 1392 | 0.050 |
Why?
|
| Antibodies, Neutralizing | 2 | 2023 | 1896 | 0.050 |
Why?
|
| New England | 1 | 2006 | 1027 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 15010 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3054 | 0.050 |
Why?
|
| Immune System Diseases | 1 | 2005 | 256 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3166 | 0.050 |
Why?
|
| Emigrants and Immigrants | 1 | 2009 | 530 | 0.050 |
Why?
|
| Babesiosis | 1 | 2003 | 92 | 0.050 |
Why?
|
| RNA-Binding Proteins | 1 | 2011 | 1885 | 0.050 |
Why?
|
| Borrelia burgdorferi | 1 | 2003 | 175 | 0.050 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2024 | 434 | 0.050 |
Why?
|
| CDC2 Protein Kinase | 1 | 1992 | 213 | 0.050 |
Why?
|
| Specimen Handling | 1 | 2006 | 694 | 0.050 |
Why?
|
| Flucytosine | 1 | 2021 | 32 | 0.050 |
Why?
|
| Hypotension | 1 | 1997 | 863 | 0.050 |
Why?
|
| Histoplasma | 1 | 2020 | 39 | 0.050 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2020 | 1349 | 0.050 |
Why?
|
| Infant | 4 | 2023 | 35448 | 0.050 |
Why?
|
| Causality | 1 | 2007 | 1232 | 0.050 |
Why?
|
| Mycophenolic Acid | 1 | 2022 | 333 | 0.040 |
Why?
|
| Bone Marrow Cells | 1 | 2008 | 2412 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2013 | 5895 | 0.040 |
Why?
|
| Cyclosporine | 1 | 2022 | 751 | 0.040 |
Why?
|
| Primary Prevention | 1 | 2007 | 1167 | 0.040 |
Why?
|
| Cell Cycle | 2 | 1992 | 2921 | 0.040 |
Why?
|
| Transplantation, Homologous | 2 | 2022 | 4617 | 0.040 |
Why?
|
| Multigene Family | 1 | 1992 | 1076 | 0.040 |
Why?
|
| Heart Arrest | 1 | 2009 | 1483 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2022 | 785 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2022 | 6459 | 0.040 |
Why?
|
| Recurrence | 2 | 2015 | 8373 | 0.040 |
Why?
|
| Amino Acid Sequence | 4 | 2006 | 13493 | 0.040 |
Why?
|
| Capsules | 1 | 2019 | 193 | 0.040 |
Why?
|
| Prognosis | 2 | 2011 | 29072 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 14537 | 0.040 |
Why?
|
| Isoantibodies | 1 | 2022 | 638 | 0.040 |
Why?
|
| Internship and Residency | 1 | 2018 | 5763 | 0.040 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2021 | 482 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 3642 | 0.040 |
Why?
|
| Prevalence | 1 | 2015 | 15306 | 0.040 |
Why?
|
| Molecular Sequence Data | 4 | 2006 | 17674 | 0.040 |
Why?
|
| Developing Countries | 2 | 2013 | 2804 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2006 | 3721 | 0.040 |
Why?
|
| Lyme Disease | 1 | 2003 | 620 | 0.040 |
Why?
|
| Pyrrolidines | 1 | 2019 | 333 | 0.040 |
Why?
|
| Quinoxalines | 1 | 2019 | 286 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2006 | 6091 | 0.040 |
Why?
|
| Drug Resistance, Microbial | 1 | 2020 | 851 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2021 | 9596 | 0.040 |
Why?
|
| Time Factors | 3 | 2018 | 39589 | 0.040 |
Why?
|
| Patient Selection | 1 | 2009 | 4192 | 0.040 |
Why?
|
| Brain | 2 | 2019 | 26597 | 0.040 |
Why?
|
| Jejunum | 1 | 2019 | 468 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2022 | 779 | 0.030 |
Why?
|
| Latin America | 1 | 2018 | 387 | 0.030 |
Why?
|
| Antilymphocyte Serum | 1 | 2018 | 474 | 0.030 |
Why?
|
| Skin | 1 | 2010 | 4392 | 0.030 |
Why?
|
| Child, Preschool | 4 | 2017 | 41383 | 0.030 |
Why?
|
| Kidney Neoplasms | 1 | 2013 | 4271 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2018 | 775 | 0.030 |
Why?
|
| Nifurtimox | 1 | 2015 | 14 | 0.030 |
Why?
|
| Carbapenems | 1 | 2017 | 119 | 0.030 |
Why?
|
| Host-Parasite Interactions | 1 | 2018 | 295 | 0.030 |
Why?
|
| Trypanocidal Agents | 1 | 2015 | 38 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 4 | 2013 | 6058 | 0.030 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2020 | 607 | 0.030 |
Why?
|
| Aspergillus flavus | 1 | 2015 | 14 | 0.030 |
Why?
|
| Scedosporium | 1 | 2015 | 10 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2017 | 953 | 0.030 |
Why?
|
| DNA, Viral | 2 | 2013 | 2172 | 0.030 |
Why?
|
| Hepatitis B Core Antigens | 1 | 2015 | 89 | 0.030 |
Why?
|
| DNA, Protozoan | 1 | 2015 | 226 | 0.030 |
Why?
|
| Waiting Lists | 1 | 2019 | 716 | 0.030 |
Why?
|
| Nitroimidazoles | 1 | 2015 | 112 | 0.030 |
Why?
|
| Curriculum | 2 | 2018 | 3621 | 0.030 |
Why?
|
| Hepatitis B Antibodies | 1 | 2015 | 154 | 0.030 |
Why?
|
| Acute Disease | 1 | 2005 | 7116 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2007 | 3185 | 0.030 |
Why?
|
| Administration, Topical | 1 | 2016 | 688 | 0.030 |
Why?
|
| India | 1 | 2020 | 2245 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2019 | 1957 | 0.030 |
Why?
|
| Personal Satisfaction | 1 | 2018 | 636 | 0.030 |
Why?
|
| Lamivudine | 1 | 2015 | 351 | 0.030 |
Why?
|
| Oropharynx | 1 | 2014 | 128 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2010 | 7785 | 0.030 |
Why?
|
| Enteral Nutrition | 1 | 2019 | 769 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2019 | 2614 | 0.030 |
Why?
|
| Canada | 1 | 2018 | 2088 | 0.030 |
Why?
|
| Viral Load | 1 | 2021 | 3297 | 0.030 |
Why?
|
| Adolescent | 4 | 2021 | 86212 | 0.030 |
Why?
|
| Cohort Studies | 3 | 2021 | 40505 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2019 | 1529 | 0.020 |
Why?
|
| Paranasal Sinuses | 1 | 2014 | 263 | 0.020 |
Why?
|
| DNA | 2 | 2024 | 7199 | 0.020 |
Why?
|
| Stem Cell Transplantation | 1 | 2020 | 1597 | 0.020 |
Why?
|
| European Union | 1 | 2012 | 156 | 0.020 |
Why?
|
| Nucleocapsid Proteins | 1 | 2011 | 75 | 0.020 |
Why?
|
| Hemolysin Proteins | 1 | 2011 | 111 | 0.020 |
Why?
|
| Geography | 1 | 2013 | 654 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 2142 | 0.020 |
Why?
|
| HIV | 1 | 2017 | 1585 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 20145 | 0.020 |
Why?
|
| Fellowships and Scholarships | 1 | 2018 | 1087 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2019 | 1949 | 0.020 |
Why?
|
| Genotype | 1 | 2024 | 12775 | 0.020 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2017 | 1024 | 0.020 |
Why?
|
| Vaccines, Inactivated | 1 | 2009 | 180 | 0.020 |
Why?
|
| HIV Infections | 3 | 2017 | 16937 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2021 | 4160 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2019 | 4187 | 0.020 |
Why?
|
| Health Personnel | 1 | 2022 | 3214 | 0.020 |
Why?
|
| Genes, p53 | 1 | 1990 | 713 | 0.020 |
Why?
|
| Fever | 2 | 2008 | 1604 | 0.020 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 1990 | 238 | 0.020 |
Why?
|
| Phylogeny | 1 | 2015 | 2737 | 0.020 |
Why?
|
| Neutropenia | 1 | 2013 | 880 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2021 | 3669 | 0.020 |
Why?
|
| Internationality | 1 | 2013 | 979 | 0.020 |
Why?
|
| Splenomegaly | 1 | 2008 | 188 | 0.020 |
Why?
|
| Heat-Shock Proteins | 1 | 2011 | 798 | 0.020 |
Why?
|
| Pancytopenia | 1 | 2008 | 101 | 0.020 |
Why?
|
| Lung | 2 | 2021 | 9843 | 0.020 |
Why?
|
| Neurology | 1 | 2014 | 767 | 0.020 |
Why?
|
| Europe | 1 | 2013 | 3354 | 0.020 |
Why?
|
| Arenaviridae Infections | 1 | 2006 | 53 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2008 | 339 | 0.020 |
Why?
|
| Diagnosis-Related Groups | 1 | 2007 | 449 | 0.020 |
Why?
|
| Bacterial Toxins | 1 | 2011 | 927 | 0.020 |
Why?
|
| Resource Allocation | 1 | 2007 | 339 | 0.020 |
Why?
|
| Virus Replication | 1 | 2013 | 2452 | 0.020 |
Why?
|
| Osteosarcoma | 1 | 1990 | 875 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 1958 | 0.020 |
Why?
|
| Social Class | 1 | 2013 | 1966 | 0.010 |
Why?
|
| Mutation | 2 | 2024 | 29620 | 0.010 |
Why?
|
| Erythrocyte Inclusions | 1 | 2003 | 4 | 0.010 |
Why?
|
| Hematologic Diseases | 1 | 2008 | 493 | 0.010 |
Why?
|
| Radiography | 1 | 2015 | 6939 | 0.010 |
Why?
|
| Mice | 2 | 2011 | 80065 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 1990 | 2887 | 0.010 |
Why?
|
| Guideline Adherence | 1 | 2013 | 2188 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2006 | 2563 | 0.010 |
Why?
|
| Sweating | 1 | 2003 | 154 | 0.010 |
Why?
|
| Anemia, Hemolytic | 1 | 2003 | 161 | 0.010 |
Why?
|
| Cricetinae | 1 | 2006 | 2426 | 0.010 |
Why?
|
| Cloning, Molecular | 2 | 1992 | 4172 | 0.010 |
Why?
|
| Urine | 1 | 2003 | 354 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2017 | 4673 | 0.010 |
Why?
|
| Pharyngitis | 1 | 2003 | 217 | 0.010 |
Why?
|
| Pregnancy | 1 | 2023 | 29296 | 0.010 |
Why?
|
| Genetic Complementation Test | 1 | 1992 | 555 | 0.010 |
Why?
|
| Abdominal Pain | 1 | 2008 | 1054 | 0.010 |
Why?
|
| Hospitalization | 1 | 2021 | 10327 | 0.010 |
Why?
|
| Age Factors | 1 | 2018 | 18145 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1992 | 1058 | 0.010 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2012 | 1860 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 1992 | 750 | 0.010 |
Why?
|
| Sarcoma | 1 | 1990 | 1794 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2011 | 4480 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2017 | 21676 | 0.010 |
Why?
|
| Suicide, Attempted | 1 | 1997 | 1232 | 0.010 |
Why?
|
| Critical Care | 1 | 2011 | 2662 |